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Abstract
Background: 3, 39diindolylmethane (DIM), a natural phytochemical, has shown inhibitory effects on the growth and
migration of a variety of cancer cells; however, whether DIM has similar effects on vascular smooth muscle cells (VSMCs)
remains unknown. The purpose of this study was to assess the effects of DIM on the proliferation and migration of cultured
VSMCs and neointima formation in a carotid injury model, as well as the related cell signaling mechanisms.
Methodology/Principal Findings: DIM dose-dependently inhibited the platelet-derived growth factor (PDGF)-BB-induced
proliferation of VSMCs without cell cytotoxicity. This inhibition was caused by a G0/G1 phase cell cycle arrest demonstrated
by fluorescence-activated cell-sorting analysis. We also showed that DIM-induced growth inhibition was associated with the
inhibition of the expression of cyclin D1 and cyclin-dependent kinase (CDK) 4/6 as well as an increase in p27
Kip1 levels in
PDGF-stimulated VSMCs. Moreover, DIM was also found to modulate migration of VSMCs and smooth muscle-specific
contractile marker expression. Mechanistically, DIM negatively modulated PDGF-BB-induced phosphorylation of PDGF-
recptorb (PDGF-Rb) and the activities of downstream signaling molecules including Akt/glycogen synthase kinase(GSK)3b,
extracellular signal-regulated kinase1/2 (ERK1/2), and signal transducers and activators of transcription 3 (STAT3). Our in vivo
studies using a mouse carotid arterial injury model revealed that treatment with 150 mg/kg DIM resulted in significant
reduction of the neointima/media ratio and proliferating cell nuclear antigen (PCNA)-positive cells, without affecting
apoptosis of vascular cells and reendothelialization. Infiltration of inflammatory cells was also inhibited by DIM
administration.
Conclusion: These results demonstrate that DIM can suppress the phenotypic modulation of VSMCs and neointima
hyperplasia after vascular injury. These beneficial effects on VSMCs were at least partly mediated by the inhibition of PDGF-
Rb and the activities of downstream signaling pathways. The results suggest that DIM has the potential to be a candidate
for the prevention of restenosis.
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Introduction
Atherosclerosis is the primary pathological event leading to
decreases in arterial lumen size. The thrombotic complications of
atherosclerosis, such as myocardial infarction and stroke, are the
leading causes of death in both middle- and high-income countries
and are among the top five causes of death in low-income
countries [1]. Great efforts have been made to find efficient
therapies to overcome atherosclerotic obstructive disease. Percu-
taneous coronary intervention (PCI), which has advanced over the
past decades, can restore blood flow in these vessels. Nevertheless,
restenosis of the artery following PCI is the major factor
hampering the long-term success of the procedure. Drug eluting
stents (DES) can reduce the restenosis rate to less than 10% [2,3];
however, emerging evidence suggests that DES has the potential
drawback of impairing reendothelialization and increasing the risk
of late thrombosis [4,5]. These drawbacks have prompted the
search for new compounds that can efficiently inhibit restenosis
with fewer side effects.
Neointima formation is a crucial process in restenosis. During
neointima development after vascular injury, growth and pro-
thrombotic factors released from platelets and leucocytes trigger
the migration of vascular smooth muscle cells (VSMCs) from the
media to the intima, where they proliferate and undergo
phenotypic changes. Excessive VSMC proliferation, migration
and phenotypic modulation underlie the major pathophysiologic
mechanism responsible for the failure of restenosis after PCI [6,7].
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typic modulation may provide useful approaches to improve
existing therapeutic strategies for restenosis.
Epidemiological studies have shown that increased consumption
of vegetables and fruits is associated with a lower risk of all-cause,
cancer, and cardiovascular disease death [8,9]. Phytochemicals
harvested from vegetables and fruits have received increasing
attention recently, and the use of phytochemicals in combination
therapies has been considered as one of several novel treatment
approaches. One of the most promising bioactive phytochemicals
is indole-3-carbinol (I3C), which is produced from cruciferous
vegetables, such as cauliflower and broccoli. In the acidic
environment of the stomach, I3C is susceptible to oligomerization
and converted into a number of condensation products, including
a dimeric product, 3,39diindolylmethane (DIM), its major active
metabolite [10]. DIM has shown inhibitory effects on the growth
of a variety of cancer cells, including breast, prostate, thyroid,
lung, and cervical cancers, with negligible levels of toxicity [11–
15].
The molecular mechanism by which DIM confers its biological
effects has been extensively investigated. It is becoming clear that
DIM has pleiotropic effects on multiple signaling targets related to
control of the cell cycle, apoptosis, signal transduction, oncogen-
esis, hormonal homeostasis, and transcription regulation. In vitro
studies have indicated that DIM is a potent inhibitor of complexes
of cyclin and cyclin-dependent kinases (CDKs) and is responsible
for upregulation of CDK inhibitors. DIM also participates in the
regulation of Akt signal transduction. Inhibition of the activation
of Akt and its downstream effector, NF-kB, has been reported in
prostate cancer cells [11]. Moreover, DIM has been shown to
regulate Akt/FOXO3a/androgen receptor signaling, resulting in
the alteration of p27
Kip1 expression [16]. In addition to these
antiproliferative effects, DIM inhibits angiogenesis and invasion of
tumor cells by repressing the expression of matrix metalloprotei-
nase, adhesion molecules and urokinase-type plasminogen activa-
tor [13,17].
However, whether DIM has a direct effect on VSMC
proliferation and migration, in addition to its anticancer
properties, remains unknown. In addition, the suitability of DIM
for preventing highly proliferative vascular responses, such as
postangioplasty restenosis, needs further investigation. In the
present study, we demonstrate that DIM causes insufficient
regulation of the cell cycle proteins that control the G0/G1/S
phase progression of VSMCs and inhibit VSMC proliferation.
Moreover, DIM also inhibits the PDGF-induced migration and
phenotypic modulation of VSMCs, two other important processes
in neointima development. The mechanism by which DIM
confers its beneficial effects on VSMCs may be the blockade of
PDGF signal cascades. Finally, we demonstrate that oral
administration of DIM prevents VSMC proliferation and
neointima formation in a mouse model of vascular injury.
Materials and Methods
Materials
DIM was purchased from Sigma-Aldrich (St. Louis, MO).
Recombinant human platelet-derived growth factor-BB (PDGF-
BB) came from Prospec (Rehovot, Israel). The antibodies used to
recognize the total levels and phosphorylation of extracellular
signal-regulated kinase 1/2 (ERK1/2), Akt, glycogen synthase
kinase-3b (GSK-3b) and signal transducer and activator of
transcription 3 (STAT3) were obtained from Cell Signaling
technology (Danvers, MA). Antibody against total levels and
phosphorylation of PDGF-receptor b (PDGF-Rb), smooth muscle
alpha-actin (SM-a-actin), SM22a, CD31were purchased from
Abcam (Cambridge, MA). Anti-desmin came from Santa Cruz
Biotechnology (Santa Cruz, CA). Antibodies against CDk4, CDk6,
cyclin D1, p27
Kip1, glyceraldehyde-3-phosphate dehydrogenase
(GAPDH), and proliferating cell nuclear antigen (PCNA) were
purchased from Cell Signaling technology. Antibody against
CD45 was purchased from BD Biosceinces (San Diego, CA).
Complete protease inhibitor, PhosSTOP, Cell Proliferation
Reagent WST-1 and Cell Proliferation ELISA, BrdU (colorimet-
ric) kits were obtained from Roche Diagnostics (Mannheim,
Germany). All other reagents were purchased from Sigma-Aldrich,
except where specified. For the in vitro study, DIM was dissolved
in dimethyl sulfoxide (DMSO). DMSO alone, without DIM,
served as a control. DMSO did not show any effect on cell
viability, cell proliferation, or related molecular mechanisms (data
not shown).
Cell culture
Primary vascular smooth muscle cells were enzymatically
isolated from the thoracic aortas of male Sprague-Dawley rats
(100 to 150 g) and grown in DMEM/F12 medium containing
10% fetal bovine serum as previously described [18]. The purity of
the VSMCs was determined by the morphological characteristics
and positive staining of SM a-actin, the positive cells are over
95%. The cells used in this study were between passages 5 and 12.
The VSMCs were grown to 60% and 80% confluence and serum
starved for 24 h. Quiescent cells were pretreated with various
concentrations of DIM for 1 h prior to stimulation with PDGF-BB
(20 ng/ml). Human Umbilical Vein Endothelial Cells (HUVECs)
were purchased from ScienCell, the cells were grown in
endothelial cell medium (ScienCell). The cells used in this study
were between passages 3 and 5.
Measurement of cell proliferation and DNA synthesis
Cell proliferation was determined by the nonradioactive
colorimetric WST-1 assay according to the manufacturer’s
instructions. The VSMCs (5610
3/well) were grown to 60%
confluence and growth-arrested in a 96-well microplate. After
preincubation with various concentrations of DIM for 1 h, the
cells were treated with PDGF-BB (20 ng/ml) in the presence/
absence of DIM for 48 h and loaded with WST-1 for the final 2 h.
The cell’s color intensity was determined at 450 nm. DNA
synthesis in VSMCs was assessed by measuring the incorporation
of BrdU. The cells were seeded and treated as in the WST-1 assay.
BrdU was added for the last 2 h of treatment. BrdU incorporation
was measured with a cell proliferation ELISA kit.
Evaluation of cell viability
Trypan blue exclusion was used to determine the viability of
VSMCs and HUVECs. After addition of different concentrations
of DIM for 24 h or 48 h, VSMCs or HUVECs were trypsinized
and incubated with 0.4% trypan blue dye. Viability was assessed
by automated determination of the percentage of cells that are
able to exclude trypan Blue with a CountessH Automated Cell
Counter (Invitrogen)
Assays of cell cycle progression
Cell cycle progression was measured using propidium iodide
staining with a fluorescence-activated cell-sorting (FACS) analysis.
Briefly, cells at 70% confluence were synchronized for 24 h and
preincubated with DIM (25 mM) for 1 h, then subsequently
treated with PDGF-BB (20 ng/ml) for 24 h. The cells were then
trypsinized and fixed with 70% ethanol overnight. The fixed cells
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incubated with 1 ml propidium iodide (PI) staining buffer
(20 mg/ml PI and 50 mg/ml RNase A), and then analyzed with
FACS. The cell cycle distributions were analyzed with Multicycle
AV software (Phoenix Flow Systems, San Diego, CA).
Migration assay
The migration assay was performed using the Transwell system
(a 6.5-mm polycarbonate membrane with 8-mm pores; Corning,
NY). Fifty microliters (5610
4) of cells were seeded on the upper
chamber and attached for 30 min. The monolayers were then
treated for 1 h by adding 50 ml of 2-fold-concentrated DIM
solution to the upper chamber and 600 ml of the DIM solution
(16) to the lower chamber. PDGF-BB was added to the bottom
chamber as the chemoattractant. The cells were allowed to
migrate through the membrane to the lower surface for 6 h. Cells
on the upper surface of the membrane that had not migrated were
scraped off with cotton swabs, and cells that had migrated to the
lower surface were fixed and stained with 0.1% crystal violet/20%
methanol and counted. Migrated cell numbers were calculated as
the number of migrated cells per high-power field (2006).
Western blotting
The VSMCs were cultured in a 6-cm diameter dish and grown
to 70% to 80% confluence, then starved in serum-free medium for
24 h. The cells were then treated with DIM (25 mM) for 2 h before
exposure to 20 ng/ml PDGF-BB for the indicated time. The cells
were lysed in RIPA buffer with protease and phosphatase
cocktails. Twenty micrograms of protein extract was used for
SDS-PAGE. The proteins were then transferred to an Immobilon-
FL transfer membrane (Millipore) and probed with various
antibodies. After incubation with a secondary IRDyeH 800CW-
conjugated antibody, the signals were visualized with an Odyssey
Imaging System. Specific protein expression levels were normal-
ized to GAPDH for total protein or to total proteins for
phosphorylated protein.
Endovascular carotid artery guidewire injury
All animal experimentation protocols were performed under
institutional animal welfare guidelines and approved by the
Animal Care and Use Committee of Renmin Hospital of Wuhan
University (Permit Number: 00015816). All surgery was performed
under sodium pentobarbital anesthesia, and all efforts were made
to minimize suffering. Ten-week-old male c57BL/6 mice under-
went guidewire endothelial denudation injuries by the insertion of
a guidewire (0.38 mm in diameter, No. C-SF-15-15, Cook,
Bloomington, Indiana), as previously described [19]. Briefly, with
the use of aseptic techniques, the left carotid artery was exposed,
and the distal bifurcation of the carotid artery was encircled
proximally and ligated distally with 8-0 silk sutures. A guidewire
was introduced into the arterial lumen through a transverse
arteriotomy made between the sutures. The guidewire was then
advanced toward the aortic arch and withdrawn 5 times. After
removal of the guidewire, the proximal 8-0 suture was ligated, and
the incision was closed. Sham surgery without injury was
performed on the right side. After surgery, the mice were fed
either a normal rodent chow diet alone or a normal chow diet
containing 0.09% DIM (w/w). This diet corresponded to 150 mg/
kg DIM if a 30 g mouse consumed 5 g of chow per day. The mice
were maintained on these diets for 28 days before they were
euthanized. The right and left carotid arteries were isolated, fixed
in buffered formalin phosphate and processed for morphometric
and immunohistochemical analyses.
Evaluation of neointima formation
For morphometric analysis, 5-mm-thick paraffin-embedded
sections were cut from equally spaced intervals in the middle of
injured and control common carotid artery segments and stained
with hematoxylin and eosin to demarcate cell types. Fifteen
sections from each carotid artery were reviewed and scored under
blind conditions. The intimal (I) and medial (M) areas were
measured using the Image Pro Plus6.0 program, and the I/M
ratios were calculated.
Immunohistochemistry
Immunostaining for PCNA was performed as previously
described [20]. An anti-PCNA monoclonal antibody, comple-
mented by a biotinylated anti-mouse secondary antibody, was
applied to perfusion-fixed, paraffin-embedded tissues. The slides
were treated with an avidin-biotin block, exposed to DAB with
hematoxylin, and analyzed under a light microscope. The data
was presented as the number of PCNA-positive-stained cells within
the neointima. For fluorescent immunohistochemistry, sections
were incubated with primary antibodies at 4uC overnight. After
incubation with FITC-conjugated secondary antibody, the slides
were observed by fluorescent microscopy. The apoptotic VSMCs
were detected by terminal deoxynucleotidyl transferase-mediated
dUTP nick endlabelling (TUNEL) according to the supplier’s
instructions (In situ cell death detection kit, Roche, Mannheim,
Germany). Picrosirius red was stained for collagen deposition.
Statistical analysis
The results were expressed as means6SEM. Statistical analysis
was performed using one-way analysis of variance (ANOVA),
followed by Dunnett’s multiple comparison tests. A value of
P,0.05 was considered significant.
Results
DIM inhibits VSMC proliferation stimulated by PDGF-BB
Abnormal proliferation of VSMCs is known to contribute to
vascular lesion formation. DIM has been proven to be an
antitumor compound that leads to growth suppression in cancer
cells; however, until now it has not been clear whether DIM has a
growth-suppressing effect on VSMCs. We first evaluated the effect
of DIM on cell proliferation with a WST-1 cell proliferation assay.
Stimulation with PDGF-BB for 48 h increased VSMC prolifera-
tion by approximately 2.5-fold compared with untreated controls
(Figure 1A). DIM prevented the increase in VSMC numbers in a
dose-dependent manner. Higher concentrations of DIM (50 mM)
almost completely blocked the PDGF-BB-induced cell prolifera-
tion. Cells treated with DIM (5 to 50 mM) for 48 h in the absence
of PDGF-BB showed no significant difference in the viability of
VSMCs compared with the untreated cells, which suggests that
DIM is not cytotoxic at the concentrations tested (Figure 1A). We
further investigated the inhibitory effect of DIM on DNA
synthesis. Figure 1B illustrates the results from a BrdU
incorporation assay and shows that PDGF treatment increased
DNA synthesis in VSMCs, DIM significantly inhibited DNA
synthesis in a dose-dependent manner, and DNA replication was
almost completely blocked in VSMCs treated with DIM at
concentrations of 25 or 50 mM, compared with PDGF alone
(Figure 1B).
Effect of DIM on viability of VSMC and HUVEC
To exclude a cell cytotoxicity effect of DIM, we determined cell
necrosis by trypan blue exclusion in the absence or presence of
DIM. As shown in Figure 2A and Figure S1A, DIM did not induce
3,39Diindolylmethane Prevents Neointima Formation
PLoS ONE | www.plosone.org 3 April 2012 | Volume 7 | Issue 4 | e34957cell necrosis of VSMCs up to 48 h. Furthermore, the antiprolif-
erative effect of DIM was reversible: cells were serum-starved and
synchronized in the presence or absence of DIM for 24 h. After
removing DIM, cells were than stimulated with PDGF-BB for
24 h, and BrdU incorporation was quantified. Cells pretreated
with DIM (25 mM) showed an almost similar proliferation rate as
cells pretreated with control buffer only (Figure 2C). In contrast,
cells pretreated with H202 (400 mM) did not proliferate in the
presence of PDGF-BB. These data indicate that there is no toxic
effect of DIM in the tested concentrations.
Because reendothelialization is a vital process for arterial injury
repair, we tested the influence of DIM on endothelial cell viability.
HUVECs were incubated in the absence or presence of DIM for
24 h or 48 h before their viability was analyzed according to their
ability to exclude trypan Blue (Figure 2B and Figure S1B). The
results showed that DIM had no negative influence on endothelial
cell viability.
DIM Prevents Cell Cycle Entry/Progression in the G0/G1
phase
DIM’s effect on cell cycle progression was analyzed to elucidate
the mechanisms responsible for its antiproliferative effect. As
revealed by flow cytometry, 25 mM DIM significantly increased
the fraction of G0/G1 phase cells but decreased the numbers of S
phase cells in VSMCs, which indicated that DIM prevented cell
cycle entry/progression in the G0/G1 phase (Figures 3A and 3B).
This result suggests that DIM acts at the early stages of cell cycle
progression.
DIM inhibits cyclin, CDK expression and p27
Kip1
degradation induced by PDGF-BB
Cell cycle progression is tightly regulated through specific CDK-
cyclin complexes [21]. We found that DIM inhibited cell
proliferation and caused G1 cell cycle arrest; cyclin D1, CDK4
and CDK6 may be the targets of DIM action. As shown in
Figure 3C, the expression of cyclin D1, CDK4 and CDK6 was
induced by PDGF-BB (20 ng/ml), while DIM treatment (25 mM)
significantly decreased expression of these molecules (Figure 3C).
We next assessed the effect of DIM on the induction of p27
Kip1,
which inactivates the cyclin-CDK complexes in the G1 phase,
leading to cell cycle arrest. P27
Kip1 was constitutively expressed in
serum-starved quiescent VSMCs and was downregulated by
PDGF-BB. In contrast, pretreatment with DIM partly restored
p27
Kip1 expression (Figure 3C).
DIM prevents PDGF-BB-stimulated VSMCs migration
Migration of smooth muscle cells from the media to the intimal
region is another important component of vascular lesion
formation. We next examined whether DIM played a role in
regulating VSMCs migration. As indicated in Figure 4A, treat-
ment with PDGF-BB (20 ng/ml) caused an almost 2-fold increase
in the migration of VSMCs; however, pretreatment with DIM
Figure 1. DIM prevents VSMC proliferation and DNA synthesis induced by PDGF-BB. VSMCs were serum starved for 24 h and then treated
with the indicated concentrations of DIM (5 to 50 mM) for 48 h in the absence or presence of PDGF-BB (20 ng/ml). A. Cell viability was examined with
the WST-1 test. The data are expressed as the mean OD4506SEM (#P,0.01 versus control group; *P,0.01 versus PDGF alone; n=6). B. BrdU
incorporation was determined with an ELISA-based assay. DNA synthesis is expressed as the mean OD3706SEM (#P,0.01 versus control group;
*P,0.01 versus PDGF alone; n=6).
doi:10.1371/journal.pone.0034957.g001
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number of migrated cells was significantly decreased by DIM
(Figure 4B). These results suggest that DIM is a potent inhibitor of
VSMC migration.
The effect of DIM on phenotypic modulation of VSMCs
Pathological conditions such as atherosclerosis, restenosis, and
hypertension are associated with phenotypic modulation of
VSMCs, which is characterized by loss of contractility, abnormal
proliferation, migration, and matrix secretion [22]. Phenotypically
modulated VSMCs exhibit decreased expression of a variety of
contractile genes, including SM a-actin, SM22a, and desmin. To
further evaluate the phenotypic modulation of VSMCs by DIM,
western blot analysis was used to detect differentiated phenotype
markers. After pretreatment with DIM (25 mM) for 2 h, quiescent
VSMCs were stimulated with PDGF-BB (20 ng/ml) for 48 h in
the presence/absence of DIM. As indicated in Figure 5, PDGF
reduced the protein levels of SM a-actin, SM22a, and desmin.
Moreover, pretreatment with DIM partially blocked the repressive
effects of PDGF-BB, which suggests that DIM contributes to
maintaining the quiescent (differentiated) state of VSMCs.
Molecular mechanisms involved in DIM inhibition of
VSMC proliferation and migration
We then analyzed the molecular mechanisms of the phenotypic
modulation of DIM in VSMCs. Previous studies have demon-
strated that the mitogen-activated protein kinase (MAPK) and
phosphatidylinositol 3-kinase (PI3K)/Akt signal transduction
pathways are critically involved in VSMC proliferation and
migration. Therefore, we first evaluated the effect of DIM on the
PDGF-induced activation of the Akt/GSK3b pathways. The cells
were treated with PDGF-BB, and phosphorylation of Akt/GSK3b
was detected. Our data showed that PDGF-BB induced rapid and
sustained phosphorylation of Akt and GSK3b without affecting
their total levels (Figure 6 and Figure S2). We then examined the
effects of DIM on the kinetics of PDGF-BB-induced Akt/GSK3b
activation. The cells were pretreated with 25 mM DIM for 2 h and
then treated with PDGF-BB for the indicated time. As shown in
Figure 6, PDGF-BB-induced Akt and GSK3b phosphorylation
was slightly but statistically significantly impaired by DIM. The
observed inhibitory effects of DIM on PDGF-BB-induced Akt/
GSK3b activation were not due to decreases in total protein levels.
We then examined the effects of DIM on the PDGF-BB-induced
activation of the ERK1/2 pathways. DIM showed a marked
decrease in the PDGF-BB induced phosphorylation of ERK1/2 in
the same pattern as decrease in Akt phosphorylation (Figure 6 and
Figure S2).
STAT3 is thought to play a role in the regulation of cell growth
and differentiation. Accordingly, VSMC stimulation with PDGF-
BB produced a strong STAT3 activation, as demonstrated by the
phosphorylation of STAT3. In contrast, preincubation with DIM
(25 mM) significantly attenuated STAT3 phosphorylation (Figure 6
and Figure S2).
DIM was shown to inhibit the downstream components of
PDGF-BB such as ERK1/2, Akt and STAT3 phosphorylation
Figure 2. Effect of DIM on viability of VSMC and HUVEC. A. VSMCs were incubated in growth medium in the absence or presence of different
concentrations of DIM for 24 hours, and cell viability was evaluated by counting the number of cells that excluded the trypan blue dye (P=NS versus
control group; n=4). B, HUVECs were incubated in growth medium in the absence or presence of different concentrations of DIM for 24 hours, and
cell viability was evaluated by trypan blue exclusion (P=NS versus control group; n=4). C, VSMCs were incubated in the absence or presence of DIM
(25 mM) or H202 (400 mM, serving as positive control) for 24 hours. After 3 washing steps, cells were then stimulated with PDGF-BB for 24 hours, and
VSMC proliferation was quantified by BrdU incorporation (P=NS versus pretreated with control buffer; n=6).
doi:10.1371/journal.pone.0034957.g002
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be a potential target for DIM. As shown in Figure 6 and Figure S2,
pre-treatment with DIM significantly inhibited the PDGF-Rb
phosphorylation(Tyr857) that was induced by PDGF-BB. The
observed inhibitory effects of DIM on PDGF-induced PDGF-Rb
phosphorylation were not due to the reduction in total protein
levels.
The effects of DIM on neointima formation and cell
proliferation in vivo
To evaluate the effects of DIM on neointima formation, mouse
carotid arteries were harvested 28 days after injury and subjected
to morphometric analysis. Representative sections from control
and DIM-treated injured carotid arteries are shown in Figure 7A.
DIM inhibited neointima formation 28 days after guidewire injury
to the carotid arteries (Figures 7A, C and D). The neointima area
Figure 3. DIM prevents cell cycle progression in VSMCs. VSMCs were grown with DIM (25 mM) in the absence or presence of PDGF-BB (20 ng/
ml) for 24 h, and cell cycle distribution was evaluated with flow cytometric analysis. A. Representative cell cycle profiles are shown. B. Quantification
of VSMCs in the G0/G1, S, and G2/M phases, as determined by flow cytometric evaluation, is shown (#P,0.01 versus control group; *P,0.01 versus
PDGF alone; n=3). C. Cell cycle protein expression was measured with western blot analysis. GAPDH detection served as a loading control.
doi:10.1371/journal.pone.0034957.g003
Figure 4. DIM inhibits PDGF-BB-induced cell migration. A. VSMCs were cultured in a cell migration filter insert and stimulated with PDGF-BB
for 6 h with or without DIM treatment (25 mM). B. Cellular migration was determined by counting the cells that migrated through the pores. The
results are expressed as means6SEM (#P,0.01 versus control group; *P,0.01 versus PDGF alone).
doi:10.1371/journal.pone.0034957.g004
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compared with the injured controls (n=6) at 28 days after carotid
injury (intimal area: 5,458.26606 mm
2 versus 15,036.761,220.7 mm
2;
I/M ratio: 0.2660.02 versus 0.7560.1). To assess VSMC growth,
arterial sections were stained with anti-PCNA antibody and analyzed.
DIM also significantly suppressed cell proliferation, as indicated by a
reduced number of PCNA-positive cells 28 days after carotid injury
(132.1167.45 in controls, n=9; 8466.449 in the DIM group, n=9)
( F i g u r e7 Ba n dE ) .
The effects of DIM on VSMC reendothelialization,
apoptosis and inflammation in vivo
Given our data with HUVECs in vitro, we also investigated the
effect of DIM on the reendothelialization of injured carotid
arteries in vivo. Immunostaining of CD31 showed that the extent
of reendothelialization was equivalent between control and DIM
group at day 7 and day 28 after injury, confirming that
administration of DIM did not impair reendothelialization
(Figure 8A and B).
We also investigated whether DIM affected infiltration of
inflammatory cells in injured vascular tissues. The number of
CD45 positive cells in the injured vessels was significantly
attenuated in DIM-administered mice (Figure 8C).
To evaluate the effect of DIM on cell apoptosis, TUNEL-
positive cells were quantified. DIM did not augment apoptosis of
VSMCs (Figure 8D). These results suggest minor contribution of
apoptosis to the inhibition of neointima growth by DIM.
Sirius Red staining revealed that the collagen fibers were
abundant in neointima and media tissues in both groups, there
were no detectable differences in extracellular matrix (ECM)
components between two groups (Figure 8E).
Discussion
In this study, we characterized the biological effects of DIM on
VSMCs in vitro and in vivo in injured mouse arteries. We
demonstrated that DIM lessened PDGF-BB-induced VSMC
phenotypic modulation and the development of neointima
formation after vascular injury. We provided evidence that DIM
stabilized p27
Kip1 and downregulated cyclin D1. Subsequently,
DIM prevented the proliferation and migration of VSMCs. These
beneficial effects of DIM on VSMCs are associated with the
inhibition of PDGF-Rb phosphorylation and its downstream
signaling pathways, including the MAPK, Akt/GSK-3b and
STAT3 pathways. The efficiency of DIM was also observed in
vivo because oral administration of DIM effectively prevented
neointima formation in a murine model of wire-induced vascular
injury. These results suggest that DIM might be a novel therapy
for preventing injury-induced vascular remodeling.
It is well established that excessive VSMC proliferation and
migration in the arterial walls plays a pivotal role in the
development of neointima; therefore, inhibiting pathological
VSMC proliferation and migration is a critical step in preventing
Figure 5. Effect of DIM on the regulation of smooth muscle
gene expression. A. VSMCs preincubated for 2 h with DIM and then
stimulated with PDGF-BB (20 ng/ml) for 48 h. The protein levels of SM
a-actin, SM22a, and desmin were determined with western blot analysis
and quantified by densitometry. B. Bar graphs showing the quantifi-
cation of western blots. The results are expressed as a percentage of
control (#P,0.05 versus control group; *P,0.05 versus PDGF alone;
n=3).
doi:10.1371/journal.pone.0034957.g005
Figure 6. Inhibitory effects of DIM on PDGF-Rb, Akt, GSK-3b, ERK1/2, and STAT3 activation in the PDGF-BB-stimulated VSMCs.
Serum-starved VSMCs were stimulated with PDGF-BB for an indicated time in the absence or presence of DIM (25 mM). The protein levels of phospho-
PDGF-Rb, PDGF-Rb, phospho-Akt, Akt, phospho-GSK-3b, GSK-3b, phospho-ERK1/2, ERK1/2, phospho-STAT3, and STAT3 were determined with
western blot analysis. One representative image out of 3 independently performed experiments is shown.
doi:10.1371/journal.pone.0034957.g006
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demonstrated that DIM inhibited VSMC proliferation and
PDGF-BB-induced DNA synthesis in a concentration-dependent
manner. This antiproliferative effect of DIM was not due to
cellular cytotoxicity, as demonstrated by the evans blue exclusion.
Cell proliferation is primarily controlled by regulation of the cell
cycle. A growing body of evidence demonstrates that DIM causes
cell cycle arrest in a variety of cancer cell lines; therefore, we
hypothesized that DIM would block VSMC proliferation through
cell cycle arrest. As we expected, our results showed that DIM
treatment for 24 h led to G1 phase arrest, exhibited by a
significant accumulation of cells in the G0/G1 phase and a
reduction of cells in the S phase, which indicate that DIM inhibits
cell cycle progression quite early in the G0/G1 phase. Modulation
of the expression and function of cell cycle regulatory proteins
provides an important mechanism for inhibiting cell growth. The
D-type cyclins combine and activate CDK4 and CDK6 to
phosphorylate and inactivate retinoblastoma (Rb) protein, which
induces progression through the G1 phase of the cell cycle [21].
The activity of the cyclin/CDK complex depends on the balance
of cyclins and CDK inhibitors (CKIs). One of the CKIs, p27
Kip1,
can bind to and inhibit a wide spectrum of cyclin/CDK
complexes, including cyclin D-CDK4/6 and cyclin E-CDK2,
and arrest cell growth at the G1 – G1/S boundary. Our
experiment indicated that DIM treatment resulted in significant
downregulation of cyclin D1-CDK4/6 and upregulation of
p27
Kip1, consistent with the inhibitory effect of DIM on VSMC
proliferation. These observations suggest that the antiproliferative
activity of DIM involves a multifaceted attack on multiple target
molecules critically involved in growth inhibition. Over the last
decade, several observations have shown a close link between cell
cycle progression and cell migration. In addition to their
involvement in cell cycle regulation, cyclin D1 and p27
Kip1 have
been reported as cell migration regulators. Previous studies have
demonstrated that cyclin D1 promotes cell migration both in vitro
and in vivo [23,24], whereas reductions in cyclin D1 levels blocked
PDGF-BB-induced migration. Cyclin D1 exerts its anti-migratory
effect by inhibiting Rho-activated kinase II and thrombospondin 1
[23]. Unlike the consistent role of cyclin D1 in cell migration, the
effects of p27
Kip1 on cell migration are controversial. Besson et al.
postulated that these differences may depend on cell type-specific
variations in the relative balance between Rho and Rac activities
and in the molecular interactions and subcellular localization of
RhoA [25]. Results from different research groups have
demonstrated that p27
Kip1 inhibits cell migration in VSMCs
[26,27]. In the present study, DIM-induced upregulation of
p27
Kip1 and downregulation of cyclin D1 expression were
consistent with DIM’s inhibitory effect on VSMC migration.
These results suggest that the effects of DIM on cyclin D1 and
p27
Kip1 expression may also involved in inhibiting VSMC
migration. However, VSMC migration is a complicated process
involving various signaling pathways and effector molecules; the
exact role and mechanism of cell cycle protein in the process of
inhibition of migration by DIM needs further investigation. On
the whole, our study suggests that protection against neointima
thickening by DIM might result from a combination of growth
suppression and migration blockade.
Figure 7. DIM prevents neointima formation induced by guidewire injury. A–B. Representative sections of the injured carotid artery of
either an animal from the control group or the DIM-treated group are shown. C–D. Quantification of the intimal area and I/M ratios of carotid arteries
of mice from either the control group or the DIM-treated group (n=6, *P,0.01 versus injured control). E. Quantification of PCNA-positive cells of
carotid arteries of mice from either the control group or the DIM-treated group (n=9; *P,0.01 versus injured control).
doi:10.1371/journal.pone.0034957.g007
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activation. In response to vascular injury, the phenotype of
VSMCs changes from quiescent, differentiated, and contractile to
less differentiated and synthetic [28]. In addition to increased
proliferation and migration, dedifferentiated VSMCs demonstrate
decreased expression of smooth muscle-specific contractile mark-
ers, such as SM a-actin, SM22a and desmin [22]. This
dedifferentiated phenotype contributes to the pathogenesis of
restenosis after PCI. It is well established that PDGF-BB is a key
mediator of VSMC phenotypic switching [29]. In accordance with
previous studies, we observed that PDGF-BB decreased SM a-
actin, SM22a and desmin expression, apart from enhanced
VSMC proliferation and migration. More importantly, our in
vitro study demonstrated that DIM treatment partly rescued the
expression of SM a-actin, SM22a and desmin, accompanied by
reduced cell proliferation and migration. These results suggest that
DIM may halt the change toward a deleterious VSMC phenotype
induced by PDGF-BB, which in turn contributes to the
suppression of neointima formation.
Given that phenotypic modulation of VSMCs contributes to the
formation of advanced atherosclerotic lesions and in-stent
restenosis, DIM may be beneficial in these vascular injuries. In
the present study, we used a well-established carotid injury model
to investigate DIM’s ability to protect against the neointima
response to vascular injury. We demonstrated that DIM
attenuated the increase in PCNA-positive cells in the neointima
region and significantly reduced intimal hyperplasia upon injury to
the mouse carotid artery. In addition to the antiproliferative effect,
DIM was demonstrated to inhibit inflammatory cell recruitment,
which may further contribute to the effective reduction of vascular
lesion formation. These results bolstered our in vitro findings and
provided direct evidence to support the notion that DIM could
protect against pathological vascular remodeling after vascular
injury. In our study, DIM was initiated after vascular injury and
was able to prevent vascular remodeling; these results increase the
clinical relevance of our findings. Furthermore, our data indicated
that DIM neither induce apoptosis of VSMC nor exert toxic effect
on VSMC. In addition, DIM did not show cytotoxic effect on
HUVEC in vitro and did not affect reendothelialization in vivo.
Therefore, due to its practicality and safety as a potential
therapeutic application, DIM may represent an attractive
molecule for treating vascular remodeling.
Although the entire mechanism of DIM-induced modulation of
VSMC activity remains unclear, according to our study, DIM’s
effect on VSMCs is considered to be at least partly due to the
inhibition of the Akt/GSK-3b, ERK1/2 and STAT3 signal
pathways. Akt has various downstream targets, including GSK-3b.
It is known that activated Akt phosphorylates GSK3b and
decreases its catalytic activity [30]. The Akt/GSK3b pathway is
implicated in multiple cellular processes, including migration and
proliferation events downstream from growth factors, such as
PDGF. We examined the activation of this signaling pathway.
Figure 8. Effect of DIM on reendothelialization, inflammation, apoptosis, and extracellular matrix deposition in vivo. A.
Representative immunohistochemical staining for CD31 at day 7 and day 28 after injury. B, Quantitative analysis showed no difference in the extent of
reendothelialization between the 2 groups (n=6, P=NS versus injured control, *P,0.05 versus day 7). C. Infiltration of inflammatory cells at 7days
after vascular injury. Inflammatory cells were immunostained with anti-CD45 antibody. Arrows indicate positive cells (n=6, *P,0.05 versus injured
control). D. Apoptotic cells were assessed by TUNEL method at 7 days after injury. Arrows indicate TUNEL-positive cells. E. Sirius red staining of injured
vessels (28 days). Collagen fibers were stained in red.
doi:10.1371/journal.pone.0034957.g008
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sustained activation of Akt/GSK3b. More importantly, pretreat-
ment with DIM facilitated the dephosphorylation of Akt and its
substrate GSK3b, which meant the inactivation of Akt and
reversed activation of GSK3b. GSK-3b activation has been found
to induce cyclin D1 export from the nucleus to the cytoplasm for
proteolysis, which decreases the availability of cyclin D1 [31].
Furthermore, GSK-3b could inhibit the translocation of the
nuclear factor of activated T cells (NFAT) into the nucleus, which
was recently found to induce cyclin D1 expression [24]. GSK-3b
inhibition also has been shown to decrease expression of the CDK
inhibitor p27
Kip1 [32]. Moreover, Bianchi et al. have found that
GSK-3b phosphorylates serine residues in focal adhesion kinase
(FAK) to negatively modulate FAK catalytic activity, which is
important in cell migration [33]. Based on these results, it is
possible that the inactivation of Akt/GSK3b contributes to DIM’s
biological effects.
We also examined DIM’s effect on the activation of ERK1/2
and STAT3, two other important players implicated in PDGF-
BB-induced VSMC proliferation and migration. The ERK1/2
pathway has been found to participate in PDGF-induced
downregulation of p27
Kip1 and subsequent cell proliferation
[34]. STAT3 can directly regulate cyclin D1 transcription [35].
Moreover, it appears that STAT3 activation is involved in VSMC
inflammation and neointima formation [36,37]. In a similar way,
DIM also attenuated PDGF-stimulated phosphorylation of
ERK1/2 and STAT3, this indicates that ERK1/2 and STAT3
are also potential targets of DIM.
The ability of DIM to inhibit PDGF-stimulated Akt, ERk and
STAT3 phosphorylation suggests that DIM may mediate its effects
on PDGF signaling by acting upstream of these molecules. PDGF
binds to its cognate receptor, the PDGF-Rb, leading to its
phosphorylation on multiple tyrosine residues. This results in the
recruitment and activation of specific signaling molecules,
including ERK1/2, PI3K/Akt and STAT [38]. In the present
study, we found a direct inhibitory effect of DIM on the
phosphorylation of PDGF-Rb. which might account for its
profound in vivo effects. The mechanisms underlying the
inhibition of PDGF-Rb activity by DIM needs further investiga-
tion.
In summary, our data indicate that DIM inhibits VSMC
phenotypic modulation induced by PDGF-BB and attenuates
neointima formation in response to vascular injury. This process is
associated with an inhibition in cyclin D1 expression and an
increase in p27
Kip1 accumulation via blockade of PDGF-Rb
phosphorylation and its downstream signal transduction. The
present study suggest a potential of DIM as part of a therapeutic
strategy for vascular proliferative disease, however, its safety
especially during long term systemic application needs further
evaluation.
Supporting Information
Figure S1 Effect of DIM on viability of VSMCs and HUVECs.
A. VSMCs were incubated in growth medium in the absence or
presence of different concentrations of DIM for 48 h, and cell
viability was evaluated by counting the number of cells that
excluded the trypan blue dye (P=NS versus control group; n=4).
B, HUVECs were incubated in growth medium in the absence or
presence of different concentrations of DIM for 48 h, and cell
viability was evaluated by trypan blue exclusion (P=NS versus
control group; n=4).
(TIF)
Figure S2 Inhibitory effects of DIM on PDGF-Rb, Akt, GSK-
3b, ERK1/2, and STAT3 activation in PDGF-BB-stimulated
VSMCs. Bar graphs showing the quantification of the Western
blots; results are expressed as percentages of the control (*P,0.05
versus PDGF alone, n=3).
(TIF)
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